Decision Date:
March 2015



  • NICE TA347: nintedanib for previously treated locally advanced, metastatic or locally recurrent non-small cell lung cancer. (Decision date - August 2015)
  • NICE TA379: nintedanib for treating idiopathic pulmonary fibrosis. (Decision date - February 2016)
  • NICE TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases. (Decision date - December 2021)
  • NICE TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (Decison date - March 2023)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app